Equibles does not estimate personal net worth.
Get an email with a short summary when TriSalus Life Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get TLSI alertsSean Murphy is recorded as Board Member at TriSalus Life Sciences, Inc. (TLSI) since August 10, 2023. TriSalus Life Sciences, Inc. reported in an 8-K filed October 1, 2025 that Sean Murphy resigned as member of the Board and the Science and Technology Committee of the Board, effective September 30, 2025. TriSalus Life Sciences, Inc. reported in an 8-K filed January 8, 2025 that Sean Murphy was appointed Chief Manufacturing, Strategy and Business Development Officer, effective January 6, 2025. TriSalus Life Sciences, Inc. reported in an 8-K filed August 16, 2023 that Sean Murphy was appointed director, effective August 10, 2023. Equibles holds 4 filed executive changes naming Sean Murphy; each is listed under recent activity with its source filing. The proxy statement of TriSalus Life Sciences, Inc. reports total compensation of $2,312,533 for Sean Murphy in fiscal 2024, including a base salary of $529,513. Disclosed compensation is on record for 3 fiscal years. Sean Murphy has spoken on 5 earnings calls across 1 company, most recently for TriSalus Life Sciences, Inc. on November 14, 2024. TriSalus Life Sciences, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at TriSalus Life Sciences, Inc. includes Mary Szela (CEO and Board Member), Karim Karti (Chairman), Mats Wahlström (Chairman and Board Member) and 7 others.
“On September 30, 2025, Sean Murphy informed the Board of Directors (the "Board") of TriSalus Life Sciences, Inc. (the "Company") of his decision to resign from his position as a member of the Board and the Science and Technology Committee of the Board, effective immediately.”
“On January 4, 2025, the Board of Directors (the "Board") of TriSalus Life Sciences, Inc. (the "Company") approved, effective January 6, 2025, a leadership transition, promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company, and appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer.”
“As Mary mentioned at the top of the call, TriSalus achieved outstanding performance in the third quarter of 2024, driven by the continued success of the TriNav technology in the U.S. Our revenue, solely driven by the success of the TriNav device in the U.S., reached $7.3 million in the third quarter.”
“I am pleased to report that TriSalus achieved outstanding results in the second quarter that ended June 30, 2024. Our revenue, solely driven by the success of the TriNav device in the US, reached $7.4 million in the second quarter.”
“I am pleased to announce that TriSalus achieved outstanding results in the first quarter that ended March 31, 2024. Our revenue, solely driven by the success of the TriNav device in the U.S., reached $6.5 million.”
“I am pleased to announce that TriSalus achieved outstanding results in the fourth quarter that ended December 31, 2023. Our revenue, solely driven by the success of the TriNav device in the U.S., reached $5.7 million.”
“I'm pleased to announce that TriSalus achieved outstanding results in the third quarter that ended September 30, 2023. Our revenue solely driven by the success of the TriNav device reached $5.2 million.”
2025-01-06–present
2023-08-10–present
2023-08-10–2025-09-30
Start not stated–2024-07-19
Last confirmed by a filing; no departure on record
Start not stated–2025-09-30
Medical Devices · Healthcare
Board Member
2023-08-10–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | TriSalus Life Sciences, Inc. (TLSI) | Manufacturing, Strategy and Business Development Officer(\ ) | $529,513 | $2,312,533 |
| 2023 | TriSalus Life Sciences, Inc. (TLSI) | Manufacturing, Strategy and Business Development Officer(\ ) | $471,539 | $1,393,246 |
| 2022 | TriSalus Life Sciences, Inc. (TLSI) | Chief Financial Officer | $207,462 | $329,597 |
